Bioinformatics Clinical Research Protein 
Roots Analysis
AUGUST 28, 2022
Recent advances in multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging, in combination with bioinformatics and biostatistics, have been translated into several popular bioanalytical platforms, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry.
Worldwide Clinical Trials
APRIL 7, 2025
Solid tumors present a significant challenge to clinical research due to their complex and heterogeneous nature. Proactively Address Key Recruitment Challenges in Solid Tumor Clinical Research Solid tumor clinical research is challenging, especially because of tumor heterogeneity.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 16, 2022
A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. A notable issue with clinical trials is the homogeneity of the patient database. What, then, is the solution?
XTalks
NOVEMBER 7, 2022
“Liquid biopsies have demonstrated promising activity in multiple clinical settings, but the great enthusiasm and expectations around them can be harmful if not adequately managed,” said Dr. El Mustapha Bahassi, PhD, Director, Clinical Laboratory Sciences, at the global clinical research organization (CRO) Medpace.
STAT News
MARCH 6, 2023
“There isn’t a member of the board of JLF who wouldn’t rather be able to do this without charging people,” said Andrew Jacobs, who sits on the boards of the foundation and NorRD Bio, a small Cambridge bioinformatics firm that helps make the vaccines. “It really was a choice of this or nothing.”
The Pharma Data
SEPTEMBER 1, 2020
study investigator and Professor of Clinical Neurology, University of California San Francisco (UCSF) Weill Institute for Neurosciences and clinical research director, UCSF MS Center. Inhibition of drug transporter breast cancer resistance protein has no effect on the pharmacokinetics of major active metabolites of ozanimod.
Expert insights. Personalized for you.
52 
Let's personalize your content